These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37028478)

  • 21. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
    Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
    Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
    Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
    J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower Lactate Levels and Lower Intracellular pH in Patients with
    Wenger KJ; Steinbach JP; Bähr O; Pilatus U; Hattingen E
    AJNR Am J Neuroradiol; 2020 Aug; 41(8):1414-1422. PubMed ID: 32646946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
    Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
    J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
    Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
    Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
    Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
    Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
    Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
    Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
    Kebir S; Lazaridis L; Weber M; Deuschl C; Stoppek AK; Schmidt T; Mönninghoff C; Blau T; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Stuschke M; Antoch G; Sure U; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Herrmann K; Glas M
    Clin Nucl Med; 2019 Jun; 44(6):e375-e381. PubMed ID: 30985412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.
    Paech D; Windschuh J; Oberhollenzer J; Dreher C; Sahm F; Meissner JE; Goerke S; Schuenke P; Zaiss M; Regnery S; Bickelhaupt S; Bäumer P; Bendszus M; Wick W; Unterberg A; Bachert P; Ladd ME; Schlemmer HP; Radbruch A
    Neuro Oncol; 2018 Nov; 20(12):1661-1671. PubMed ID: 29733378
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.